Original Article

Journal of Investigative Dermatology (1996) 107, 51–56; doi:10.1111/1523-1747.ep12297888

Type 4 Phosphodiesterase Inhibitors Have Clinical and In Vitro Anti-inflammatory Effects in Atopic Dermatitis

Jon M Hanifin1, Sai C Chan1, John B Cheng2, Susan J Tofte1, William R Henderson Jr3, Deborah S Kirby2 and Ethan S Weiner2

  1. 1Oregon Health Sciences University, Department of Dermatology, Portland, Oregon, U.S.A.
  2. 2Pfizer Central Research, Groton, Connecticut, U.S.A.
  3. 3University of Washington, Department of Medicine, Seattle, Washington, U.S.A.

Received 27 November 1995; Revised 4 March 1996; Accepted 5 March 1996.

Top

Abstract

Increased cyclic AMP-phosphodiesterase activity in peripheral blood leukocytes is associated with the immune and inflammatory hyperreactivity that characterizes atopic dermatitis. Atopic phosphodiesterase has high sensitivity to a variety of enzyme inhibitors, suggesting an increased therapeutic advantage. The objective of this study was to use in vitro assays to identify a potent phosphodiesterase inhibitor and then to investigate its effectiveness in treating atopic dermatitis. Leukocyte enzyme activity was measured by radioenzyme assay, whereas prostaglandin E2 and interleukins 10 (IL-10) and 4 (IL-4) were measured in 24-h culture supernatants of mononuclear leukocytes by immunoassays. The effect of a topical phosphodiesterase Inhibitor on atopic dermatitis lesional skin was assessed by double-blind, paired comparisons of active drug and placebo ointments applied to symmetrically involved sites over a 28-d period. Using in vitro assays, we demonstrated the ability of selective high-potency phosphodiesterase inhibitors to reduce prostaglandin E2, IL-10, and IL-4 production in atopic mononuclear leukocyte cultures. We selected the Type 4 phosphodiesterase inhibitor, CP80,633, based on its inhibitory potency, for clinical testing by topical, bilateral paired comparisons in 20 patients with atopic dermatitis and demonstrated significant reductions of all inflammatory parameters. Phosphodiesterase inhibitors modulate several pathways contributing to the exaggerated immune and inflammatory responses, which characterize atopic dermatitis. This in vivo demonstration of anti-inflammatory efficacy may provide a useful alternative to the over-reliance on corticosteroid therapy in atopic disease.

Keywords:

IL-10M, IL-4, monocytes, PDE

Top

References

  1. Beavo, JA: Multiple isozymes of cyclic nucleotide phosphodiesterase. Adv Cyc Nuc Res 22: 1–38, 1988
  2. Beavo, JA: In: Beavo J, Houslay MD (eds.). Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action. Multiple Phosphodiesterase Isoenzymes: Background, Nomenclature and Implications John Wiley & Son, New York, pp 3–15, 1990
  3. Butler, JM, Chan, SC, Stevens, SR, Hanifin, JM: Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. J Allergy Clin lmmunol 71: 490–497, 1983
  4. Chan, SC, Hanifin, JM: Differential inhibitor effects on cyclic AMP phosphodiesterase isotorms in atopic and normal leukocytes. J Lab Clin Med 121: 44–51, 1993 | PubMed | ISI | ChemPort |
  5. Chan, SC, Kim, J-W, Henderson, WR, Hanifin, JM: Altered prostaglandin E2 regulation of cytokine production in atopic dermatitis. J Immunol 151: 3345–3352, 1993 | PubMed | ISI | ChemPort |
  6. Cohan, VL, Showell, HJ, Pettipher, ER, Fisher, DA, Pazoles, CJ, Watson, JW, Turner, CR, Cheng, JB: In vitro pharmacology of the novel type IV phosphodiesterase (PDE IV) inhibitor. CP80,633. J Allergy Clin Immunol 95: 350, 1995
  7. Cooper, KD, Kang, KF, Chan, SC, Hanifin, JM: Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. J Invest Dermatol 84: 477–482, 1985 | Article | PubMed | ChemPort |
  8. Geissler, FT, Kuzan, FB, Faustman, EM, Henderson, WR Jr: Lipid mediator production by post-implantation rat embryos in vitro. Prostaglandins 38: 145–155, 1989
  9. Giustina, TA, Chan, SC, Baker, JW, Hanifin, JM: Increased leukocyte sensitivity to PDE inhibitors in atopic dermatitis: tachyphylaxis after theophylline therapy. J Allergy Clin Immunol 74: 252–257, 1984
  10. Grewe, S, Chan, SC, Hanifin, JM: Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy CIin lmmunol 70: 452–457, 1982
  11. Hanifin, JM, Rajka, G: Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl 92: 44–47, 1980
  12. Heskel, NS, Chan, SC, Thiel, ML, Stevens, SR, Casperson, LS, Hanifin, JM: Elevated umbilical cord blood leukocyte cyclic adenosine monophosphate-phosphodies-terase activity in children with atopic parents. J Am Acad Dermatol 11: 422–426, 1984
  13. Jaffe, BM, Behrman, HR, (eds.): Hormone Radioimmunoassay 1974 Prostaglandins E, A, and F, Academic Press, New York, p 19
  14. Lapidus, CS, Schwarz, DF, Honig, PJ: Atopic dermatitis in children: Who cares? Who pays?. J Am Acad Dermatol 28: 699–703, 1993
  15. Li, SH, Chan, SC, Toshitani, A, Leung, DYM, Hanifin, JM: Synergistic effects of interleukin 4 and interferon-gamma on monocyte phosphodiesterase activity. J Invest Dermatol 99: 65–70, 1993
  16. Nassif, A, Chan, SC, Storrs, FJ, Hanifin, JM: Abnormal skin irritancy in atopic dermatitis and in atopy without dermatitis. Arch Dermatol 130: 1402–1407, 1994 | Article | PubMed | ISI | ChemPort |
  17. Ohmen, JD, Hanifin, JM, Nickoloff, BJ, Rea, TH, Wyzykowski, R, Kim, J, Jullien, D, McHugh, T, Nassif, AS, Chan, SC, Modlin, RL: Overexpression of IL-10 in atopic dermatitis: contrasting cytokine pattents with delayed-type hypersensitivity reactions. J Immunol 154: 1956–1963, 1995 | PubMed | ISI | ChemPort |
  18. Sampson, HA: Pathogenesis of eczema. Clin Exp Allergy 20: 459, 1990 | PubMed | ISI | ChemPort |
  19. Shmunes, E, Keil, JE: Occupational dermatoses in South Carolina: a descriptive analysis of cost variables. J Am Acad Dermatol 9: 801–866, 1983
  20. Szentivanyi, A: The beta-adrenergic theory of the atopic abnormality in bronchial asthma. J Allergy 42: 203–232, 1968 | ISI |
  21. Thompson, WJ, Terasaki, WL, Epstein, PM, Strada, SJ: Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular form of the enzyme. Adv Cyclic Nucleotide Res 10: 69–92, 1979 | PubMed | ChemPort |
  22. Torphy, TJ, Undem, BJ: Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 46: 512–523, 1991 | PubMed | ISI | ChemPort |

Extra navigation

.
ADVERTISEMENT